Addressing this, a multicenter study of Hansen and colleagues identified that treatment with the PD-1 inhibitor pembrolizumab resulted in favorable side effect profiles and anti-tumor activities in a patient cohort with advanced PD-L1-positive PCa [67]. Here, PDCD1 is linked to neoplasm.